ASCO® 2024 Insights: "Safety & Efficacy of First-in-Class CXCR1/2 Inhibitor SX-682 in Combination With Pembro in Patients With Metastatic Melanoma With Disease Progression on Anti-PD-1 Therapy"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Safety & Efficacy of First-in-Class CXCR1/2 Inhibitor SX-682 in Combination With Pembro in Patients With Metastatic Melanoma With Disease Progression on Anti-PD-1 Therapy"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Sapna Patel

52 views

June 19, 2024

0 Comments

2024 ASCO® Annual Meeting Insights Hub: Skin Videos

05:27

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Biomarker Analysis & Updated Clinical…

Feat. L. Burton

35:23

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

Feat. S. Patel

24:27

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and A…

Feat. Z. Eroglu

View All

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde

24:14

Masterclasses in Dermatology

Advances in the Treatment of Melanoma

Feat. D. Fisher

12:46

Stanford Medicine

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

Feat. A. Betof Warner

35:23

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

Feat. S. Patel

10:01

AAD 2024

AAD 2024 Insights: The Latest Advances in the Treatment of Melanoma

Feat. V. Sondak

11:05

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, …

Feat. D. Johnson

25:29

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Insights in Melanoma"

Feat. O. Hamid

22:58

Tarek Haykal

The Role of Adjuvant IO vs. Targeted Therapy for BRAF V600-Mutant St…

09:54

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "RELATIVITY-047 Trial 3-Year OS and MSS Ou…

Feat. H. Tawbi

18:28

Vanderbilt University Medical Center (VUMC)

NCCN Guidelines Updates for the Management of Cutaneous Melanoma: Ne…

Feat. D. Johnson

09:26

Oncology Data Advisor

The NADINA Trial - A Paradigm Shift in Melanoma Treatment

Feat. M. Hadfield

24:27

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and A…

Feat. Z. Eroglu

14:42

Jeff Yorio

Optimal Treatment for BRAF-Mutated Metastatic Melanoma

22:27

2024 ASCO® Annual Meeting Insights Hub

Developmental Therapeutics Highlights From ASCO® 2024

Feat. G. Sonpavde

08:41

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "NADINA Trial - Neoadjuvant Nivo + Ipi in …

Feat. C. Blank

11:27

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Curing Stage IV Melanoma - Where Have We B…

Feat. P. Corrie

17:07

MSKCC 2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis

Melanoma Brain Metastases: Successes, Failures, and Future Opportuni…

Feat. M. Postow

28:32

West Virginia State Rheumatology Society

Checkpoint Inhibitors, Arthritis and Other Autoimmune Triggers

Feat. J. Bustamante

23:09

Total Health

Key Updates in Skin Melanoma

Feat. R. Seedor

07:23

Mees Egeler

Login

Login

Join VuMedi

ASCO® 2024 Insights: "Safety & Efficacy of First-in-Class CXCR1/2 Inhibitor SX-682 in Combination With Pembro in Patients With Metastatic Melanoma With Disease Progression on Anti-PD-1 Therapy"

2024 ASCO® Annual Meeting Insights Hub: Skin Videos

Related Content